Previous 10 | Next 10 |
Post-Hoc Analysis of SOLOIST-WHF Clinical Data Published in Journal of the American College of Cardiology: Heart Failure Risk Reductions of Approximately 50% Demonstrated for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions at 30- and 90-Days F...
2023-08-03 22:01:09 ET Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Carrie Siragusa - Vice President of Marketing Lonnel Coats - Chief Executive Officer Jeffrey Wade - President and Chief Fin...
2023-08-03 16:09:08 ET Lexicon Pharmaceuticals press release ( NASDAQ: LXRX ): Q2 GAAP EPS of -$0.22. Revenue of $0.32M. As of June 30, 2023, Lexicon had $256.7 million in cash and investments, as compared to $138.4 million as of December 31, 2022. For further de...
INPEFA TM (sotagliflozin) receives FDA approval for the treatment of heart failure INPEFA granted broad label across full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes LX9211 moving i...
THE WOODLANDS, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2023 financial results on Thursday, August 3 rd , 2023 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ...
THE WOODLANDS, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Diane E. Sullivan has been elected to its Board of Directors. Ms. Sullivan brings extensive commercialization, strategy, and market access experience to the Lexi...
2023-07-13 08:30:00 ET Summary June 2023 saw significant insider purchases in Lucid Group, Diversified Healthcare Trust, Akoya Biosciences, and Axon Enterprise. The Public Investment Fund bought $1.8 billion worth of shares in Lucid Group, increasing its ownership to 74.95%. Diver...
First late-stage study will be a Phase 2b dose optimization study, with extension to run in parallel with next-stage Phase 3 studies Feedback obtained from U.S. Food and Drug Administration (FDA) Conference Call and Webcast on Monday, June 26, 2023, at 8:00 am Eastern Ti...
2023-06-23 17:09:25 ET Gainers: Morningstar ( MORN ) +8% . Annexon ( ANNX ) +5% . Cardlytics ( CDLX ) +4% . MeiraGTx Holdings ( MGTX ) +4% . Lexicon Pharmaceuticals ( LXRX ) +3% . Losers: Lulu's Fashion Lounge ( L...
2023-06-23 08:25:00 ET Conformis ( CFMS ) +91% surges ~90% after acquisition deal by restor3d. Nauticus Robotics ( KITT ) +35% Contracted by Petrobras to Develop and Test the AUV Aquanaut in Brazil. Trupanion ( TRUP ) +17% stock movers today: SoFi Technol...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...
New analysis of the pivotal Phase 3 SOLOIST-WHF trial provides additional evidence of positive economic impact on hospitals participating in various alternative payment models (APM) Findings consistent with two peer-reviewed studies published in June 2024 THE WOODLANDS, Texa...